<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611115</url>
  </required_header>
  <id_info>
    <org_study_id>15-4-167</org_study_id>
    <nct_id>NCT02611115</nct_id>
  </id_info>
  <brief_title>Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.</brief_title>
  <acronym>OptIPeCT</acronym>
  <official_title>Optimizing Tube Voltage Settings and Injection Parameters for the Individual Patient in CT Pulmonary Angiography.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Computed tomographic pulmonary angiography (CTPA) is considered the gold standard for the
      diagnosis of pulmonary embolism (PE). PE is a potentially fatal disease in which a thrombus
      is lodged into a pulmonary artery blocking blood flow and potentially leading to respiratory
      distress, acute right cardiac failure or death. Therefore early and correct diagnosis is
      crucial.

      The diagnostic and clinical value of CTPA has already been firmly substantiated.
      Unfortunately up to 7.3% of PE scans are still deemed to be non-diagnostic, for example due
      to insufficient contrast enhancement in the target arteries.

      Therefore future research should focus on two important aspects of CT imaging. On the one
      hand optimal enhancement for the individual patient, on the other hand preventing additional
      risk of CT imaging - namely contrast induced nephropathy (CIN) and radiation risk. Thus the
      purpose of our study will be to optimize radiation dose settings (e.g. tube voltage, tube
      current) and CM application for the individual patient in CTPA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Image quality</measure>
    <time_frame>one year</time_frame>
    <description>Evaluation of subjective and objective image quality based on individualized CTPA protocols</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of radiation dose</measure>
    <time_frame>one year</time_frame>
    <description>Effect of individualized tube voltage settings on radiation</description>
  </secondary_outcome>
  <enrollment type="Actual">235</enrollment>
  <condition>Pulmonary Embolism</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients referred for CTPA with a clinical suspicion of pulmonary embolism will
        be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspicion of pulmonary embolism

        Exclusion Criteria:

          -  Severe allergy against Iopromide or any of the ingredients, previous severe CM
             reaction (according to current ESUR guidelines), renal insufficiency, pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Marco Das</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Multidetector Computed Tomography</keyword>
  <keyword>Radiation Dosage</keyword>
  <keyword>Contrast Media</keyword>
  <keyword>Individualized Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

